MN1 proto-oncogene, transcriptional regulator
Last updated 13 Nov 2020
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The MN1 gene provides instructions for making a protein whose function is unclear. The MN1 protein interacts with other proteins known as transcription factors. These proteins attach to specific areas of DNA and help control the activity of particular genes. Based on its interaction with transcription factors, the MN1 protein is thought to play a role in regulating the activity of other genes, particularly those that are needed for the development of the skull and brain.
Video picks for GenesVideo library
Normal function
The MN1 gene provides instructions for making a protein whose function is unclear. The MN1 protein interacts with other proteins known as transcription factors. These proteins attach to specific areas of DNA and help control the activity of particular genes. Based on its interaction with transcription factors, the MN1 protein is thought to play a role in regulating the activity of other genes, particularly those that are needed for the development of the skull and brain.
Conditions referring to this gene or chromosome
Other names
MGCR
MGCR1
MGCR1-PEN
Patient picks for Genes

Health news
Influencers are promoting dangerous peptides on social media – and regulators are struggling to keep up
Once confined to niche bodybuilding forums and hardcore gyms, unproven injectable peptides are now being openly marketed online to the average gym-goer by social media influencers – and regulators struggling to keep up. Across Instagram, TikTok or YouTube, unapproved and harmful peptide products are being promoted as shortcuts to fat loss, anti-ageing, health and recovery and muscle growth. Peptides actually occur naturally in our body. They regulate a variety of important functions, including metabolism, appetite, hormone production and tissue repair. Synthetic versions of peptides are also used in some medicines, which are legitimate and have been clinically proven. These include GLP-1s (which are used for weight loss and managing diabetes) and insulin. But a booming, parallel “grey market” now exists online for unapproved peptide compounds. These products are primarily being sold by so-called wellness brands and in influencer-led storefronts. Many of these products are marketed as cutting-edge solutions for optimising health and body enhancement. The problem is that many of these substances have not undergone full clinical safety evaluation and are not approved for human use. Many have also been found to be contaminated with other harmful ingredients. Unapproved injectable peptides therefore pose serious health risks. Some of the risks they may pose00092-0/abstract) include nausea, vomiting, abdominal pain, gastrointestinal issues, headaches and fatigue or weakness. Immune issues, as well as allergic reactions and infections have also been reported. Moreover, there’s a clear lack of rigorous human safety data. Yet these risks often aren’t disclosed by the people selling them.
by Luke Cox

Treatment and medication
Proton pump inhibitors
Proton pump inhibitors reduce the amount of acid made by the stomach. They are commonly used to treat acid reflux and ulcers of the stomach and part of the gut called the duodenum. Most people who take a proton pump inhibitor do not develop any side-effects.
by Dr Philippa Vincent, MRCGP
Related patient information and medicines

Patient information leaflet
Medical negligence
Complaints should normally be made within 12 months of the date of the event that you're complaining about, or as soon as you ... There is a separate Health Service Ombudsman for England, Scotland, Wales and Northern Ireland. Governing bodies for health professionals Healthcare professionals are regulated by governing bodies, which have the power.

Patient information leaflet
Astigmatism
The cornea and lens are typically smooth and round in shape, but in people with astigmatism, they are irregularly shaped. Vision problems, such as astigmatism, are also known as refractive errors. Astigmatism is a common condition that can be corrected by glasses or contact lenses, or cured with laser eye surgery. Astigmatism astigmatism.

Patient information leaflet
Myopia
The medical name for short-sightedness is myopia. Eyesight problems, such as myopia, are also known as refractive errors. S hort- sightedness leads to blurred vision when looking at things at a distance, whilst close vision is usually normal. S hort- sightedness is a very common problem that can be corrected by glasses, contact lenses, or laser.

Patient information leaflet
Proton pump inhibitors
They are commonly used to treat acid reflux and ulcers of... Most people who take a proton pump inhibitor do not develop any side-effects. What are proton pump inhibitors. Proton pump inhibitors (PPIs) are a group (class) of medicines that work on the cells that line the stomach, reducing the production of acid. Types of proton pump inhibitors.
Further reading and references
- MN1 proto-oncogene, transcriptional regulator; MedlinePlus, National Library of Medicine.
- Mak CCY, Doherty D, Lin AE, Vegas N, Cho MT, Viot G, Dimartino C, Weisfeld-Adams JD, Lessel D, Joss S, Li C, Gonzaga-Jauregui C, Zarate YA, Ehmke N, Horn D, Troyer C, Kant SG, Lee Y, Ishak GE, Leung G, Barone Pritchard A, Yang S, Bend EG, Filippini F, Roadhouse C, Lebrun N, Mehaffey MG, Martin PM, Apple B, Millan F, Puk O, Hoffer MJV, Henderson LB, McGowan R, Wentzensen IM, Pei S, Zahir FR, Yu M, Gibson WT, Seman A, Steeves M, Murrell JR, Luettgen S, Francisco E, Strom TM, Amlie-Wolf L, Kaindl AM, Wilson WG, Halbach S, Basel-Salmon L, Lev-El N, Denecke J, Vissers LELM, Radtke K, Chelly J, Zackai E, Friedman JM, Bamshad MJ, Nickerson DA; University of Washington Center for Mendelian Genomics; Reid RR, Devriendt K, Chae JH, Stolerman E, McDougall C, Powis Z, Bienvenu T, Tan TY, Orenstein N, Dobyns WB, Shieh JT, Choi M, Waggoner D, Gripp KW, Parker MJ, Stoler J, Lyonnet S, Cormier-Daire V, Viskochil D, Hoffman TL, Amiel J, Chung BHY, Gordon CT. MN1 C-terminal truncation syndrome is a novel neurodevelopmental and craniofacial disorder with partial rhombencephalosynapsis. Brain. 2020 Jan 1;143(1):55-68. doi: 10.1093/brain/awz379.
- Mak CCY, Fung JLF, Lee M, Lin AE, Amiel J, Doherty D, Gordon CT, Chung BHY. MN1 C-Terminal Truncation Syndrome. 2020 Aug 13. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK560443/
- Miyake N, Takahashi H, Nakamura K, Isidor B, Hiraki Y, Koshimizu E, Shiina M, Sasaki K, Suzuki H, Abe R, Kimura Y, Akiyama T, Tomizawa SI, Hirose T, Hamanaka K, Miyatake S, Mitsuhashi S, Mizuguchi T, Takata A, Obo K, Kato M, Ogata K, Matsumoto N. Gain-of-Function MN1 Truncation Variants Cause a Recognizable Syndrome with Craniofacial and Brain Abnormalities. Am J Hum Genet. 2020 Jan 2;106(1):13-25. doi: 10.1016/j.ajhg.2019.11.011. Epub 2019 Dec 12.
- Shao H, Cen J, Chen S, Qiu H, Pan J. Myeloid neoplasms with t(12;22)(p13;q12)/MN1-EVT6: a systematic review of 12 cases. Ann Hematol. 2018 Mar;97(3):417-424. doi: 10.1007/s00277-017-3208-2. Epub 2017 Dec 22.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

